Effectiveness of interventions to improve adverse drug reaction reporting by healthcare professionals over the last decade: A systematic review.
Journal
Pharmacoepidemiology and drug safety
ISSN: 1099-1557
Titre abrégé: Pharmacoepidemiol Drug Saf
Pays: England
ID NLM: 9208369
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
01
07
2019
revised:
27
08
2019
accepted:
11
09
2019
pubmed:
15
11
2019
medline:
21
10
2020
entrez:
15
11
2019
Statut:
ppublish
Résumé
Various strategies have been studied in the literature to address the significant underreporting of adverse drug reactions (ADRs) in healthcare systems worldwide. We conducted a systematic review of the literature that assessed the impact of various strategies to improve ADR reporting published in the last decade and compared this with the strategies identified in a previous systematic review. MEDLINE and EMBASE databases were used to retrieve papers published from 01 July 2010 to 17 June 2019. We included papers in the English language that investigated the quantitative impact of strategies used to improve ADR reporting. A total of 10,021 articles were retrieved using our search criteria, of which 13 met the inclusion criteria. Multifaceted strategies resulted in a point estimate increase in ADR reporting of 9.26-fold (-2.21-17.11, 95% CI) versus 7.19-fold (-5.29-32.68, 95% CI) for single interventions. Using electronic reporting tools was more commonly identified as an interventional strategy with a point estimate increase of 13.69-fold (-5.29-32.68, 95%CI) versus 4.42-fold (0.66-8.19, 95% CI) for traditional educational methods. The quality of the majority of publications included in this review was low. Developments in digital technology in the last decade has led to the increased use of electronic reporting tools to improve ADR reporting. Higher quality studies investigating the impact of these electronic methods are needed to fully explore its role in improving ADR reporting.
Sections du résumé
BACKGROUND
Various strategies have been studied in the literature to address the significant underreporting of adverse drug reactions (ADRs) in healthcare systems worldwide.
OBJECTIVES
We conducted a systematic review of the literature that assessed the impact of various strategies to improve ADR reporting published in the last decade and compared this with the strategies identified in a previous systematic review.
METHODS
MEDLINE and EMBASE databases were used to retrieve papers published from 01 July 2010 to 17 June 2019. We included papers in the English language that investigated the quantitative impact of strategies used to improve ADR reporting.
RESULTS
A total of 10,021 articles were retrieved using our search criteria, of which 13 met the inclusion criteria. Multifaceted strategies resulted in a point estimate increase in ADR reporting of 9.26-fold (-2.21-17.11, 95% CI) versus 7.19-fold (-5.29-32.68, 95% CI) for single interventions. Using electronic reporting tools was more commonly identified as an interventional strategy with a point estimate increase of 13.69-fold (-5.29-32.68, 95%CI) versus 4.42-fold (0.66-8.19, 95% CI) for traditional educational methods. The quality of the majority of publications included in this review was low.
CONCLUSIONS
Developments in digital technology in the last decade has led to the increased use of electronic reporting tools to improve ADR reporting. Higher quality studies investigating the impact of these electronic methods are needed to fully explore its role in improving ADR reporting.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-8Subventions
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
© 2019 John Wiley & Sons, Ltd.
Références
Glossary of terms used in pharmacovigilance: Uppsala Monitoring Center; 2018 [updated 06 April 2018.
Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385-396.
Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 2016;14:10.
Sultana J, Cutroneo P, Trifiro G. Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacotherapeut. 2013;4(Suppl 1):S73-S77.
Wu C, Bell CM, Wodchis WP. Incidence and economic burden of adverse drug reactions among elderly patients in Ontario emergency departments: a retrospective study. Drug Saf. 2012;35(9):769-781.
Jolivot P-A, Hindlet P, Pichereau C, et al. A systematic review of adult admissions to ICUs related to adverse drug events. Crit Care. 2014;18(6):643.
Afifi S, Maharloui N, Peymani P, et al. Adverse drug reactions reporting: pharmacists' knowledge, attitude and practice in Shiraz, Iran. Int J Risk Saf Med. 2014;26(3):139-145.
Dorji C, Tragulpiankit P, Riewpaiboon A, Tobgay T. Knowledge of Adverse Drug Reaction Reporting Among Healthcare Professionals in Bhutan: A Cross-Sectional Survey. Drug Saf. 2016;39(12):1239-1250.
Gupta SK, Nayak RP, Shivaranjani R, Vidyarthi SK. A questionnaire study on the knowledge, attitude, and the practice of pharmacovigilance among the healthcare professionals in a teaching hospital in South India. Perspect Clin Res. 2015;6(1):45-52.
Herdeiro MT, Figueiras A, Polonia J, Gestal-Otero JJ. Physicians' attitudes and adverse drug reaction reporting: a case-control study in Portugal. Drug Saf. 2005;28(9):825-833.
Mirbaha F, Shalviri G, Yazdizadeh B, Gholami K, Majdzadeh R. Perceived barriers to reporting adverse drug events in hospitals: a qualitative study using theoretical domains framework approach. Imple Sci. 2015;10:110.
Nita Y, Batty KT, Plumridge RJ. Adverse Drug Reaction Reporting: Attitudes of Australian Hospital Pharmacists and Doctors. J Pharm Pract Res. 2005;35(1):9-14.
Varallo FR, Guimaraes Sde O, Abjaude SA, Mastroianni PC. Causes for the underreporting of adverse drug events by health professionals: a systematic review. Rev Esc Enferm USP. 2014;48(4):739-747.
Li R, Curtain C, Bereznicki L, Zaidi STR. Community pharmacists' knowledge and perspectives of reporting adverse drug reactions in Australia: a cross-sectional survey. Int J Clin Pharm. 2018;40(4):878-889.
Pillans PI. Clinical perspectives in drug safety and adverse drug reactions. Exp Rev Clin Pharmacol. 2008;1(5):695-705.
Gonzalez-Gonzalez C, Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Strategies to improve adverse drug reaction reporting: a critical and systematic review. Drug Saf. 2013;36(5):317-328.
Yoon D, Park MY, Choi NK, Park BJ, Kim JH, Park RW. Detection of adverse drug reaction signals using an electronic health records database: Comparison of the Laboratory Extreme Abnormality Ratio (CLEAR) algorithm. Clin Pharmacol Ther. 2012;91(3):467-474.
Porterfield A, Engelbert K, Coustasse A. Electronic prescribing: improving the efficiency and accuracy of prescribing in the ambulatory care setting. Perspect Health Inf Manag. 2014;11:1g.
Wong A, Plasek JM, Montecalvo SP, Zhou L. Natural Language Processing and Its Implications for the Future of Medication Safety: A Narrative Review of Recent Advances and Challenges. Pharmacotherapy. 2018;38(8):822-841.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
Page MJ, McKenzie JE, Higgins JPT. Tools for assessing risk of reporting biases in studies and syntheses of studies: a systematic review. BMJ Open. 2018;8(3):e019703.
Abadie D, Chebane L, Bert M, Durrieu G, Montastruc JL. Online reporting of adverse drug reactions: a study from a French regional pharmacovigilance center. Therapie. 2014;69(5):395-400.
Biagi C, Montanaro N, Buccellato E, Roberto G, Vaccheri A, Motola D. Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia-Romagna region). Eur J Clin Pharmacol. 2013;69(2):237-244.
Chang F, Xi Y, Zhao J, Zhang X, Lu Y. A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. J Eval Clin Pract. 2017;23(6):1316-1321.
Fang H, Lin X, Zhang J, et al. Multifaceted interventions for improving spontaneous reporting of adverse drug reactions in a general hospital in China. BMC Pharmacol Toxicol. 2017;18(1):49.
Herdeiro MT, Ribeiro-Vaz I, Ferreira M, Polonia J, Falcao A, Figueiras A. Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Saf. 2012;35(8):655-665.
Johansson ML, Hagg S, Wallerstedt SM. Impact of information letters on the reporting rate of adverse drug reactions and the quality of the reports: a randomized controlled study. BMC Clin Pharmacol. 2011;11:14.
Lander AR, Blicher TM, Jimenez-Solem E, Jespersen M, Kampmann JP, Christensen HR. Introducing an adverse drug event manager. Eur J Hospl Pharm: Sci Pract. 2013;20(2):78-81.
Linder JA, Haas JS, Iyer A, et al. Secondary use of electronic health record data: spontaneous triggered adverse drug event reporting. Pharmacoepidemiol Drug Saf. 2010;19(12):1211-1215.
Lopez-Gonzalez E, Herdeiro MT, Pineiro-Lamas M, Figueiras A. Effect of an educational intervention to improve adverse drug reaction reporting in physicians: a cluster randomized controlled trial. Drug Saf. 2015;38(2):189-196.
Morales Rios O, Jasso Gutierrez L, Talavera JO, et al. A comprehensive intervention for adverse drug reactions identification and reporting in a Pediatric Emergency Department. Int J Clin Pharm. 2016;38(1):80-87.
Ribeiro-Vaz I, Herdeiro MT, Polonia J, Figueiras A. Strategies to increase the sensitivity of pharmacovigilance in Portugal. Rev Saude Publica. 2011;45(1):129-135.
Ribeiro-Vaz I, Santos C, da Costa-Pereira A, Cruz-Correia R. Promoting spontaneous adverse drug reaction reporting in hospitals using a hyperlink to the online reporting form: an ecological study in Portugal. Drug Saf. 2012;35(5):387-394.
Terblanche A, Meyer JC, Godman B, Summers RS. Impact of a pharmacist-driven pharmacovigilance system in a secondary hospital in the Gauteng Province of South Africa. Hospital Pract (1995). 2018;46(4):221-228.
Pharmacy software vendor links to TGA adverse event reporting web service: Australian Department of Health Therapeutic Goods Administration; 2014 [17 August 2018]. Available from: https://www.tga.gov.au/media-release/pharmacy-software-vendor-links-tga-adverse-event-reporting-web-service.
Hobbs T. Access all areas: empowering patient care using TGA initiatives. Pharmacy Australia Congress October 2014.
Medicines and vaccines post-market vigilance - statistics for 2015: Australian Department of Health Therapeutic Goods Administration; 2016 [17 August 2018]. Available from: https://www.tga.gov.au/medicines-and-vaccines-post-market-vigilance-statistics-2015.
Plessis L, Gomez A, Garcia N, Cereza G, Figueras A. Lack of essential information in spontaneous reports of adverse drug reactions in Catalonia-a restraint to the potentiality for signal detection. Eur J Clin Pharmacol. 2017;73(6):751-758.
Ribeiro A, Lima S, Zampieri ME, Peinado M, Figueras A. Filling quality of the reports of adverse drug reactions received at the Pharmacovigilance Centre of Sao Paulo (Brazil): missing information hinders the analysis of suspected associations. Expert Opin Drug Saf. 2017;16(12):1329-1334.
Postmarketing Safety Reporting Requirements for Drug and Biologic Products 2015. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/postmarketing-safety-reporting-requirements-drug-and-biologic-products.
Guideline on good pharmacovigilance practices (GVP) Module VI - Collection, management and submission of reports of suspected adverse reactions to medicinal products - EMA/873138/20112017 July 2017. Available from: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports_en.pdf.
Dickersin K, Chan S, Chalmers TC, Sacks HS, Smith H Jr. Publication bias and clinical trials. Control Clin Trials. 1987;8(4):343-353.